株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

急性リンパ性白血病 (ALL - リンパ芽球性白血病):パイプライン製品の分析

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 251583
出版日 ページ情報 英文 680 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.58円で換算しております。
Back to Top
急性リンパ性白血病 (ALL - リンパ芽球性白血病):パイプライン製品の分析 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2016
出版日: 2016年11月16日 ページ情報: 英文 680 Pages
概要

急性リンパ性白血病は白血球のうちリンパ球に対する癌の一種で、急速に成長します。症状は倦怠感、皮膚紫斑、出血、息切れ、体重減少、食欲不振、骨痛、胃痛、肋骨下の痛みまたは膨満感、首または脇のしこり等で、治療には手術、放射線療法、化学療法、または併用療法が用いられます。

当レポートでは、急性リンパ性白血病(ALL:リンパ芽球性白血病)に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

  • 急性リンパ性白血病 (ALL - リンパ芽球性白血病)の概要
  • 治療薬の開発
  • 急性リンパ性白血病 (ALL - リンパ芽球性白血病):企業で開発中の治療薬
  • 急性リンパ性白血病 (ALL - リンパ芽球性白血病):大学/機関で研究中の治療薬
  • 急性リンパ性白血病 (ALL - リンパ芽球性白血病):パイプライン製品の概況
  • 急性リンパ性白血病 (ALL - リンパ芽球性白血病):企業で開発中の製品
  • 急性リンパ性白血病 (ALL - リンパ芽球性白血病):大学/機関で研究中の製品
  • 急性リンパ性白血病 (ALL - リンパ芽球性白血病)の治療薬開発に従事している企業
  • 急性リンパ性白血病 (ALL - リンパ芽球性白血病):治療薬の評価
  • 薬剤プロファイル
  • 急性リンパ性白血病 (ALL - リンパ芽球性白血病):最近のパイプライン動向
  • 急性リンパ性白血病 (ALL - リンパ芽球性白血病):休止中のプロジェクト
  • 急性リンパ性白血病 (ALL - リンパ芽球性白血病):開発が中止された製品
  • 急性リンパ性白血病 (ALL - リンパ芽球性白血病):製品開発のマイルストーン
  • 付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8640IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Lymphocytic Leukemia - Pipeline Review, H2 2016, provides an overview of the Acute Lymphocytic Leukemia (Oncology) pipeline landscape.

Acute lymphocytic leukemia (ALL) is the cancer of the white blood cells due to the production of a large number of immature lymphocytes thus blocking the production of normal blood cells. It enters the blood stream and rapidly progress to other parts of the body such as spleen, lymph nodes and liver. Risk factors for ALL include exposure to radiation or chemicals, age, virus infections and genetic factors. Symptoms include anemia, frequent infections, easy bruising, bone pain and breathing problems. Treatment includes chemotherapy, transfusions, transplant and medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acute Lymphocytic Leukemia - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Acute Lymphocytic Leukemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acute Lymphocytic Leukemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 3, 46, 42, 65 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 7, 6, 14 and 2 molecules, respectively.Acute Lymphocytic Leukemia.

Acute Lymphocytic Leukemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Lymphocytic Leukemia (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Acute Lymphocytic Leukemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Acute Lymphocytic Leukemia (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Acute Lymphocytic Leukemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Acute Lymphocytic Leukemia (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Acute Lymphocytic Leukemia (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Acute Lymphocytic Leukemia (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Overview
  • Therapeutics Development
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics under Development by Companies
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics under Investigation by Universities/Institutes
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Products Glance
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Products under Development by Companies
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Products under Investigation by Universities/Institutes
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Companies Involved in Therapeutics Development
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics Assessment
  • Drug Profiles
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Dormant Projects
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Discontinued Products
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), H2 2016
  • Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Development by Companies, H2 2016 (Contd..4)
  • Number of Products under Development by Companies, H2 2016 (Contd..5)
  • Number of Products under Development by Companies, H2 2016 (Contd..6)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Development by Companies, H2 2016 (Contd..5)
  • Products under Development by Companies, H2 2016 (Contd..6)
  • Products under Development by Companies, H2 2016 (Contd..7)
  • Products under Development by Companies, H2 2016 (Contd..8)
  • Products under Development by Companies, H2 2016 (Contd..9)
  • Products under Development by Companies, H2 2016 (Contd..10)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by 4SC AG, H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Actinium Pharmaceuticals, Inc., H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by ADC Therapeutics SA, H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Affimed GmbH , H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Altor BioScience Corporation, H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Amgen Inc., H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by ARA Healthcare Pvt. Ltd., H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Ariad Pharmaceuticals, Inc., H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Array BioPharma Inc., H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Atara Biotherapeutics, Inc., H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Bellicum Pharmaceuticals, Inc., H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Bexion Pharmaceuticals, LLC, H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Bio-Path Holdings, Inc., H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by BioSight Ltd., H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Calithera Biosciences, Inc., H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Cantargia AB, H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Celgene Corporation, H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Cellectar Biosciences, Inc., H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Cellectis S.A., H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Cellular Biomedicine Group, Inc., H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Ceronco Biosciences, H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Cielo Therapeutics Inc, H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Constellation Pharmaceuticals, Inc., H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Cyclacel Pharmaceuticals, Inc., H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by DiNonA Inc., H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Eli Lilly and Company, H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by EpiZyme, Inc., H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Erytech Pharma SA, H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Eureka Therapeutics, Inc., H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Fate Therapeutics, Inc., H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Formula Pharmaceuticals, Inc., H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Gamida Cell Ltd., H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Hangzhou Minsheng Pharmaceutical Group Co.,Ltd, H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by iDD biotech SAS, H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Immunomedics, Inc., H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Incyte Corporation, H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Intech Biopharm Ltd, H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Interprotein Corporation, H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Jasco Pharmaceuticals, LLC., H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Jazz Pharmaceuticals Plc, H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Johnson & Johnson, H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Juno Therapeutics Inc., H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Karyopharm Therapeutics, Inc., H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Kiadis Pharma N.V., H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Kite Pharma Inc, H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Les Laboratoires Servier SAS, H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by medac GmbH, H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Merck & Co., Inc., H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Mesoblast Limited, H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Moleculin Biotech Inc, H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Nanovalent Pharmaceuticals Inc., H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Novartis AG, H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by NovImmune SA, H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by NuCana BioMed Limited, H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Omeros Corporation, H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by OncoTartis, Inc., H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by OncoTherapy Science, Inc., H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Oncternal Therapeutics, Inc., H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Oribase Pharma, H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by OSE Immunotherapeutics, H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Pfenex Inc., H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Pfizer Inc., H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Pharma Mar, S.A., H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Portola Pharmaceuticals, Inc., H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Red5 Pharmaceuticals, LLC, H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Sanofi, H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Sareum Holdings Plc, H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Seattle Genetics, Inc., H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Sellas Inc, H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Shire Plc, H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Stemline Therapeutics, Inc., H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by SYNIMMUNE GmbH, H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Syros Pharmaceuticals Inc, H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by TetraLogic Pharmaceuticals, H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Theravectys SA, H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Threshold Pharmaceuticals, Inc., H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Tolero Pharmaceuticals, Inc., H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Tragara Pharmaceuticals, Inc., H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Verastem, Inc., H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by VioQuest Pharmaceuticals, Inc., H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Xbrane Biopharma AB, H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by ZIOPHARM Oncology, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Dormant Projects, H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Dormant Projects (Contd..1), H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Dormant Projects (Contd..2), H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Dormant Projects (Contd..3), H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Dormant Projects (Contd..4), H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Dormant Projects (Contd..5), H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Dormant Projects (Contd..6), H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Discontinued Products, H2 2016
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Discontinued Products (Contd..1), H2 2016

List of Figures

  • Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), H2 2016
  • Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top